News

Trump tariffs live updates: China pushes back as Bessent denies unilateral US tariff cuts
China rejected US trade overtures Thursday, demanding all tariffs be lifted and denying any progress in talks. "The US should ...
Halozyme files patent lawsuit against Merck over injectable Keytruda
Merck (MRK) stock trades flat as Halozyme Therapeutics (HALO) files patent infringement suit linked to MRK's new injectable ...
A Success Story - DelveInsight's Strategic Support to a Biopharma Leader in NSCLC Epidemiology Forecasting up to 2034, Segmented by Biomarker Types
In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company ...
IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight
DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 ...
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales
(Reuters) -Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year ...
pharmaphorum22h
FDA approves Samsung/Merck & Co's Herceptin biosimilar
The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June. Developed by Samsung ...